← Back
Data updated: Mar 10, 2026
TORRENT PHARMS
NeurologyMetabolicCardiovascular
TORRENT PHARMS is a generic drug manufacturer focused on Neurology, Metabolic, Cardiovascular. Key products include SERTRALINE HYDROCHLORIDE.
2001
Since
31
Drugs
-
Trials
609
Approved (2yr)
Recent Activity
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE 2026-02-17
Labeling
AMLODIPINE BESYLATE 2026-02-17
Manufacturing (CMC)
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 50%
2 drugs
Metabolic 25%
1 drugs
Cardiovascular 25%
1 drugs
Pipeline Strength Pro
Loading...
Active (11)
Discontinued (17)
AMLODIPINE BESYLATE OLANZAPINE CETIRIZINE HYDROCHLORIDE ALLERGY LOSARTAN POTASSIUM QUETIAPINE FUMARATE METFORMIN HYDROCHLORIDE RISPERIDONE ESCITALOPRAM OXALATE MONTELUKAST SODIUM CLOPIDOGREL BISULFATE PRAMIPEXOLE DIHYDROCHLORIDE ISOSORBIDE MONONITRATE DONEPEZIL HYDROCHLORIDE ZOLPIDEM TARTRATE FELODIPINE CITALOPRAM HYDROBROMIDE LEVOFLOXACIN
Company Info
- First Approval
- 2001-07-05
- Latest
- 2025-12-02
- Applications
- 39
FDA Sponsor Names
TORRENT PHARMSTORRENT PHARMS LTDTORRENT PHARMS LLC